---
title: "BUCHANG PHARMA: The change of drug production license for wholly-owned subsidiary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252821383.md"
description: "BUCHANG PHARMA announced that its wholly-owned subsidiary Baoding Tianhao Pharmaceutical Co., Ltd. has obtained permission from the Hebei Provincial Drug Administration to change the production scope of its \"Drug Production License,\" including modifications to the production address of oral suspensions, tablets, etc., as well as the shared Chinese medicine extraction and granules with Shandong Buchang Shenzhou Pharmaceutical Co., Ltd. This change will help optimize the production structure, maintain stable production capacity, meet market demand, and positively impact the company's future operations"
datetime: "2025-08-13T09:09:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252821383.md)
  - [en](https://longbridge.com/en/news/252821383.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252821383.md)
generator: "portal-rs"
---

# BUCHANG PHARMA: The change of drug production license for wholly-owned subsidiary

BUCHANG PHARMA announced that its wholly-owned subsidiary Baoding Tianhao Pharmaceutical Co., Ltd. has obtained permission from the Hebei Provincial Drug Administration, agreeing to the changes in its "Drug Production License" workshop production scope and drug commissioning situation. The changes include modifications to the production scope of oral suspensions, tablets, etc., at the production address, as well as the shared use of traditional Chinese medicine extraction and granules with Shandong Buchang Shenzhou Pharmaceutical Co., Ltd. The validity period is until July 7, 2030. This change is beneficial for the company to optimize its production structure, maintain stable production capacity, meet market demand, and has a positive impact on the company's future operations

### Related Stocks

- [603858.CN](https://longbridge.com/en/quote/603858.CN.md)

## Related News & Research

- [TLV: Strong H1 2026 profit growth and capital strength amid macroeconomic challenges](https://longbridge.com/en/news/296790736.md)
- [CHINA TELECOM 1H26 Net Profit Fades 14.9% to RMB19.588B, Beats Forecast; Interim DPS HKD0.1606](https://longbridge.com/en/news/296462591.md)
- [Piller signs contract with Cosun Beet for V-RISE upgrade at Dutch sugar plant](https://longbridge.com/en/news/296751243.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**